Health Canada was ordered to release specified parts of an analysis involving Pfizer while retaining protection for proprietary scientific and manufacturing information. In Health Canada (Re), 2026 OIC 43, dated May 8, 2026, the Information Commissioner of Canada found that neither the department nor Pfizer had justified withholding all the disputed information under the Access to Information Act.
The request concerned records related to an Issue Analysis Summary addressed in parliamentary Inquiry of Ministry Q-2670. Health Canada had partly withheld five pages using exemptions for third-party trade secrets, confidential financial or technical information, and anticipated financial or competitive harm.
Pfizer opposed disclosure and made representations during the investigation. Health Canada conceded that some redactions did not satisfy the exemptions. The commissioner considered both parties’ explanations and the requester’s submissions, reaching a mixed result rather than ordering publication of the entire file.
Confidential technical information remained protected
Paragraph 20(1)(b) requires four elements: the information must be financial, commercial, scientific or technical; confidential; supplied by a third party; and consistently treated as confidential by that party. All four must be established for the particular information being withheld.
The commissioner accepted that much of the disputed chemistry and manufacturing material was scientific or technical. She also accepted that it was not publicly available, had been communicated with a reasonable expectation of confidentiality, and had consistently been treated as confidential by Pfizer.
The requester argued that public-health regulation reduced the expectation of confidentiality and that the information was already public. The commissioner rejected those arguments for the protected material. Her review did not establish that further portions could reasonably be separated without revealing more than was publicly known, and she accepted the public benefit of confidentiality in the regulatory relationship.
Protection remained for categories including plasmid names, sequence locations, a table, specified manufacturing passages and appendix content apart from administrative details. The ruling does not disclose those underlying proprietary records or decide that they must all become public.
A regulator’s own views are not automatically company information
Other portions failed the exemption’s requirements. Administrative details and certain headings were not shown to be financial, commercial, scientific or technical information. Information created by Health Canada also did not become information supplied by Pfizer merely because it appeared in a document concerning the company.
The commissioner distinguished government viewpoints from comments that would reveal the actual technical information a company supplied. Some passages mixed those elements, and the decision preserved protection where severing a sentence would leave meaningless fragments or expose the confidential manufacturing content.
For the remaining government-originated information, the trade-secret exemption did not supply an alternative basis for withholding. Neither Health Canada nor Pfizer established that the specific passages were secret in the required sense. General explanations about proprietary manufacturing information did not establish secrecy for the regulator’s own views.
Fear of misunderstanding did not establish competitive harm
Paragraph 20(1)(c) requires evidence connecting disclosure of particular information to a reasonable expectation of material financial or competitive harm, beyond a mere possibility. The commissioner found that the parties had not demonstrated that connection for the remaining disputed information.
Pfizer argued that releasing the statements could mislead stakeholders and the public and cast doubt on the scientific integrity of its product design and manufacturing, particularly given Health Canada’s approval of its COVID-19 variant vaccines. The commissioner was not persuaded that the asserted risk of misunderstanding justified withholding these passages.
Relying on the access-law principles described in the reasons, she explained that an inaccurate public perception of a product’s safety does not ordinarily establish the required probable harm. A general fear that information could be taken out of context could not replace evidence satisfying the exemption.
For information that remained properly protected as confidential third-party material, the commissioner concluded that the statutory circumstances requiring consideration of public-health or public-safety disclosure under subsection 20(6) were not present. The access ruling was not a new product-safety determination or a finding of wrongdoing by Pfizer.
Limited disclosure order, not release of the entire file
The commissioner ordered disclosure of specified information under the event, knowledge and issue headings; parts of the background and analysis; and administrative details beside two figures. The order expressly preserved specified technical references within those passages.
Health Canada notified the commissioner on April 30 that it would comply, after receiving the initial report on March 31. That undertaking does not establish when the requester later received the information.
The report allowed the complainant or institution 35 business days to seek Federal Court review, followed by 10 business days for third parties if neither had applied. The orders would take effect on the 46th business day if no review were sought. This report does not independently confirm whether an application was filed or disclosure subsequently occurred.
The result draws a practical boundary between legitimate commercial confidentiality and accountability for a regulator’s own work. Protection must be justified for the actual passage, and it does not automatically extend to administrative information or government analysis simply because the surrounding file contains proprietary science.
